Log in

NASDAQ:IPXL - Impax Laboratories Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range N/A
50-Day Range
MA: $18.30
52-Week Range N/A
Volume3.04 million shs
Average Volume945,265 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Impax Laboratories, Inc, a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Impax Generics and Impax Specialty Pharma. The Impax Generics segment provides generic pharmaceutical products directly to wholesalers, retail drug chains, and others; generic prescription products through third-party pharmaceutical entities pursuant to alliance agreements; generic pharmaceutical over-the-counter (OTC) and prescription products to third parties; and generic pharmaceutical OTC products through third-party pharmaceutical companies pursuant to alliance agreements. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:IPXL



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A

Receive IPXL News and Ratings via Email

Sign-up to receive the latest news and ratings for IPXL and its competitors with MarketBeat's FREE daily newsletter.

Impax Laboratories (NASDAQ:IPXL) Frequently Asked Questions

What is Impax Laboratories' stock symbol?

Impax Laboratories trades on the NASDAQ under the ticker symbol "IPXL."

How were Impax Laboratories' earnings last quarter?

Impax Laboratories (NASDAQ:IPXL) released its earnings results on Thursday, November, 9th. The specialty pharmaceutical company reported $0.23 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.20 by $0.03. The specialty pharmaceutical company earned $206.40 million during the quarter, compared to analysts' expectations of $208.38 million. The company's revenue for the quarter was down 9.4% compared to the same quarter last year. During the same period last year, the business earned $0.37 earnings per share. View Impax Laboratories' Earnings History.

Has Impax Laboratories been receiving favorable news coverage?

News coverage about IPXL stock has been trending extremely negative recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Impax Laboratories earned a news impact score of -4.2 on InfoTrie's scale. They also gave media coverage about the specialty pharmaceutical company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Impax Laboratories.

Who are some of Impax Laboratories' key competitors?

What other stocks do shareholders of Impax Laboratories own?

Who are Impax Laboratories' key executives?

Impax Laboratories' management team includes the folowing people:
  • Mr. Bryan M. Reasons, Sr. VP of Fin. & CFO (Age 51)
  • Mr. Mark A. Schlossberg, Sr. VP, Gen. Counsel & Corp. Sec. (Age 57)
  • Mr. Michael J. Nestor, Pres of Impax Specialty Pharma Division (Age 65)
  • Mr. Douglas S. Boothe, Pres of Impax Generics Division (Age 54)
  • Mr. Paul M. Bisaro, CEO, Pres & Director (Age 57)

What is Impax Laboratories' official website?

The official website for Impax Laboratories is http://www.impaxlabs.com/.

How can I contact Impax Laboratories?

Impax Laboratories' mailing address is 30831 HUNTWOOD AVENUE, HAYWARD CA, 94544. The specialty pharmaceutical company can be reached via phone at 510-476-2000 or via email at [email protected]

MarketBeat Community Rating for Impax Laboratories (NASDAQ IPXL)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  391 (Vote Outperform)
Underperform Votes:  551 (Vote Underperform)
Total Votes:  942
MarketBeat's community ratings are surveys of what our community members think about Impax Laboratories and other stocks. Vote "Outperform" if you believe IPXL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IPXL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/7/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel